DE202005017669U1 - Antimicrobial agent, useful to treat respiratory tract related microorganisms or infectious diseases in nose-, throat- or paranasal sinuses, comprises plant drug or ethanolic/aqueous extracts (e.g. Rumex acetosa L) - Google Patents

Abstract

Antimicrobial agent (I) comprising at least one plant drug or at least an ethanolic/aqueous extracts, where the plants are Rumex acetosaL., Rumex acetosellaL., Rumex obtusifoliusL., Rumex patientiaL., Rumex crispusL., Rumicis herba, Verbena officinalis, Sambucus nigraand/or Primula veris, is new. An independent claim is also included for a kit comprising (I) in liquid or lyophilized form and at least one salt form for the preparation of nose rinsing solution. ACTIVITY : Respiratory-Gen.; Antibacterial; Virucide; Antiinflammatory. The effectiveness of (I) was tested against Staphylococcus aureus(ATCC 12600). The results showed that median lethal dosage (LD50) value of (I) was 0.78 %, by volume. MECHANISM OF ACTION : None given.

Description

The The present invention relates to an antimicrobial and / or anti-inflammatory acting agent according to the preamble of claim 1, which is at least one plant drug or at least an ethanolic / aqueous Excerpt from it contains with the plants selected are from the group consisting of: Rumex acetosa L., Rumex acetosella L., Rumex obtusifolius L., Rumex patientia L., and Rumex crispus L., (hereinafter referred to collectively as "Rumicis herba"); Verbena officinalis; Sambucus nigra; and primula veris; as well as their mixtures. The invention further relates to a use of the agent for the treatment of inflammatory and / or infectious Diseases of the nasopharynx and / or the nasal sinuses as well for the manufacture of a medicament.

The above medicinal plants are as secretolytic agents in infections of the upper Respiratory system, especially known for sinusitis.

Each individual drug contributes to the unique effectiveness of the composition:
Gentiana lutea (yellow gentian) usually uses the root medicinally. Among the ingredients are, inter alia, various Secoiridoidglykoside with expectorant effect.

From the aforementioned Rumex species, hereafter "Rumicis herba" (sorrel herb) called, are usually leaves and stems are used medicinally. This contains flavonoids, oxalic acid and various tannins as ingredients with anti-inflammatory Effect, which also the body's immune system positive support.

From Verbena officinalis (verbena) are preferably leaves and Stem medicinally used as the main ingredients iridoid glycosides, Phenylethanoidglykoside and flavonoids contain, whereby expectorant and antiviral effects are achieved.

From Sambucus nigra (Black Elderberry) typically become the flowers medicinal whose ingredients contain various flavonol glycosides and as the main active ingredient contains sambunigrin, a cyanogenic glycoside, which expectorant and antiviral by catching the flu virus spikes Cells and blocks their effects (Grabovac, A. and Ullmer, A., Austrian Apotheker-Verlagsgesellschaft m.b.H., 2003).

From Primula veris (cowslip) become flowers and goblet used medicinally. The ingredients include triterpene saponins and phenol glycosides, such as primulaverin. They have an expectorant effect and fight Viruses. The ingredients act as a mild secretolytic and expectorant in the treatment of respiratory diseases.

The combination of said medicinal plants is known as secretolytic agent under the registered trademark Sinupret ^® and on the market for about 70 years. The composition of the Sinupret ^® is preferably effective for inflammations and infections of the ear, nose and throat and is particularly suitable for the treatment of acute and chronic sinusitis.

Either Acute and chronic sinusitis are common. In three out of four make The sinusitis develops as a result of a cold with one Extension to the paranasal sinuses, which is accompanied by a mucosal inflammation.

The Respiratory tracts range from the main nasal cavity to the various sinuses to the alveoli. To the nasal sinuses counting the frontal sinuses, the ethmoidal cells, the sphenoid sinus and the maxillary sinuses.

All called bone cavities are lined with mucous membrane inside and lead through narrow openings, the ostia, in the Nasal cavity.

The surface of the respiratory tract is covered with a protective mucus, on which dirt particles and pathogens such as viruses, bacteria or fungi, which penetrate with the air, adhere. The mucus contains antibodies that attack the invading substances and render them harmless. So that the foreign substances can be flushed out of the body, the mucus is usually with the help of the flicker hairs of the ciliated epithelium are transported in the direction of the throat, where it can be swallowed.

Around to ward off infection-related respiratory diseases the mucous membrane unhindered over Protective and cleaning mechanisms have. For the removal of the with pathogens laden mucus, the unimpeded function of the cilia is indispensable, which are wavy Movements transport the mucus as well as the functional and thin mucus.

at an infection and inflammatory processes The upper respiratory tract is the protective and cleaning mechanisms of the Mucosa only more limited functioning.

example ways solve viruses such as rhinoviruses, adenoviruses or coronaviruses inflammatory reactions of the mucous membranes, causing the mucous membrane to swell up and produce increased mucus. there it comes first too watery, subsequently to viscous mucus flow. In the course of inflammation the nasal mucosa can the ostia of the sinuses Slurry and obstruct the flow of mucus or even prevent. The leads to a jam in the sinuses connected with tough Mucus, resulting in a loss of function or loss of function of the cilia leads this finally works a loss of Cleaning mechanism of the mucous membrane.

One favored such microenvironment in particular the rapid multiplication of ubiquitous microorganisms.

at longer Duration of this unfavorable Conditions, such as a swollen mucous membrane and viscous mucus sticky cilia, It can lead to chronic sinusitis, with the result of a permanent damage the mucous membrane and the ciliated epithelium.

Respiratory-related Pathogens, which also understood in particular ENT-relevant germs For example, Staphylococcus can be found in the mucus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus pneumoniae, Streptococcus mutans or Haemophilus influenzae.

In the prior art, it is for example from the DE 103 41 579 A1 Applicant is aware that extracts of Gentiana lutea have antimicrobial activity against some of the above germs.

outgoing From this prior art, it is therefore an object of the present invention Invention, further more effective and well-tolerated antimicrobial agents to provide plant-based.

The solution This object is achieved by the characterizing features of the claim 1 with respect to an antimicrobial agent.

One Kit according to claim 14 releases the task as well.

Under The above-mentioned pathogens are also found to be resistant to methicillin resistant Staphylococcus aureus strain, called MRSA. Against this Bacterium are standard antibiotics such as β-lactam antibiotics, for example Oxacillin, penicillin and amoxicillin, without effect, as with too often Use of antibiotics can develop resistance. An additional These germs carry risk to surgical intensive care units where she to pneumonia, Cause wound infections and sepsis can.

Especially the present invention relates to an antimicrobial agent, which is at least one plant drug or at least one ethanolic / aqueous Excerpt from it contains with the plants selected are from the group consisting of: Rumex acetosa L., Rumex acetosella L., Rumex obtusifolius L., Rumex patientia L., and Rumex crispus L., (hereinafter and in the claims with the collective term "Rumicis herba "); Verbena officinalis; Sambucus nigra; and primula veris; As well as their Mixtures.

These plants are together with Gentiana lutea part of sold under the well known brand names Sinupret ^® Sekretolytikums the assignee of the present application. Gentiana lutea was known to have antimicrobial activity. In the investigations of the Applicant, however, it has surprisingly been found that not only a combination of the plant species in the form of crude drugs or an ethanolic / aqueous extract thereof also a strong non-additive antimicrobial ent folds, but also every plant taken for itself.

The medicinal plants used in Sinupret ^® are specifically selected, examined and further processed. The consistent quality of the drug achieved by the manufacturer, the company BIONORICA, achieved by optimized breeding and harvesting strategies and a strict quality control.

In case of upper airway obstruction due to viscous mucus, the ingredients of the composition used (Gentiana lutea: Rumicis herba: Verbena officinalis: Sambucus nigra: Primula veris = 1: 3: 3: 3: 3) induce the formation of fresh, fluid slime, whereby the above-described process of mucus solution and the removal and reduction of the inflammatory symptoms is achieved and initiated healing process of Masenschleimhaut. Sinupret ^® thus gently restores the self-cleansing power of the respiratory tract while providing a strong antimicrobial effect. A hallmark of Sinupret ^® is its good tolerability, the BIONORICA determined dosage rarely cause side effects in the patient and no interactions with other drugs are known.

With According to the present invention, plants / plant mixtures (or ethanolic / aqueous excerpts from this) with decongestant and expectorant, as well as additionally strong antimicrobial effects provided.

in the Mucus-living and multiplying microbes (viruses, bacteria, Fungi) are killed or inhibited in their multiplication, creating an existing or new the resulting infection process is contained or even prevented.

The Antimicrobial agents of the present invention can thus advantageous in the treatment of pathogen-relevant pathogens triggered Infections are used. The expectorant and anti-inflammatory Effect is through the additional added antimicrobial effect. This causes an infection of the upper respiratory tract in addition to the release of the zähflüssigen- mite-laden mucus mitigated by killing and / or Reduction of the proliferation of bacterial pathogens contained or even completely brought to a standstill.

By the invention described above is e.g. Sinusitis diseased Patient in a gentle manner without synthetic chemical components treated. Drug is also characterized by a high degree of compatibility with regard to its Interactions with other drugs and in terms of rarely occurring side effects in compliance with BIONORICA predetermined dosage.

The antimicrobial composition of the present invention is particularly effective against respiratory-relevant pathogens, taking them especially against gram-positive cocci such as Staphylococcus aureus, Staphylococcus aureus (MRSA), Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus pneumoniae and Streptococcus mutans, against Gram-negative rod bacteria such as Haemophilus influenzae, as well as against Enterobacteriaceae faecalis shows antimicrobial activity.

The antimicrobial efficacy is by MBK values and the LD90 and / or LD50 characterizes.

With MBK is called the minimum bactericidal concentration. among them is the lowest concentration of an active ingredient to understand under in vitro conditions for a defined inoculum of bacteria within a specified Exposure time kills more than 99.9% of the introduced microorganisms.

With LD50 and LD90, the lethal doses, are the lowest concentrations an active ingredient, which within a specified Exposure time more than 50 or 90% of the introduced microorganisms kill.

MTC values Anti-microbial compositions are in the range from approx. 0.2 - 50% Vol, in particular about 0.2 - 30 % Vol, preferably about 0.2-12 % Vol and preferably about 0.2 - 3 % Vol. To be antimicrobially effective, the LD90 includes one Range of about 0.1 - 50 % Vol, especially about 0.1 - 20 % Vol, preferably about 0.1-10 % Vol and preferably about 0.1 - 3 % Vol. The LD50 moves accordingly within a range of approx. 0.1 - 50 % Vol, especially about 0.1 - 20 % Vol, preferably about 0.1-10 % Vol and preferably about 0.1 - 3 % Vol.

The antimicrobial composition preferably contains an extract from Gentiana lutea, Rumicis herba, Verbena officinalis, Sambucus nigra and primula veris in a ratio of 1: 3: 3: 3: 3.

The antimicrobial composition may be present as lyophilisate.

The galenic formulation of the antimicrobial agent may be selected from the group consisting of: drops, juice, syrup, tablets, dragees, capsules, sustained-release formulations, rectal or vaginal suppositories, infusion, spray, in particular nose and throat spray and disinfectant spray; Ointments, emulsions, powders, powders, liquid or solid preparations for inhalation, compresses, deposits, in particular wound and gum deposits, tamponades, including for teeth, rinsing solutions for nose and ear, in particular in combination with physiological and hyperosmolar concentrations of salts or salt mixtures , preferably saline, in particular sea salt or ^Emser® salt.

Of course you can the formulation is pharmaceutically customary Excipients included.

Consequently The present invention also relates to the use of the antimicrobial according to the invention By means of infections caused by respiratory pathogens and the use for the manufacture of a medicament.

Further Advantages and features of the present invention are due to the description of embodiments as well as the drawing. It shows:

1 the MBK, LD90 and LD50 of the mixture Sinupret ^® PM 03-009 examined with the pathogens;

2 the MBK, LD90 and LD50 of the mixture Sinupret ^® PM 03-009 examined with the pathogens;

3 the MBK, LD90 and LD50 of the Sinupret ^® mixture PM 04-013 in the investigated pathogens;

4 the MBK, LD90 and LD50 of the Sinupret ^® drops PM 03-010 in the investigated pathogens;

5 the MBK, LD90 and LD50 of the Sinupret ^® PM -Tropfen 04-014 in the investigated agents;

6 the MBK, LD90 and LD50 of the Tinct. Primulae flos PM 03-007;

7 the MBK, LD90 and LD50 of the Tinct. Sambuci flos PM 03-006;

8th the MBK, LD90 and LD50 of the Tinct. Rumicis herba PM 03-005; and

9 the MBK, LD90 and LD50 of the Tinct. Verbena herba PM 03-004

Examples

I. Experimental Part and proof of antimicrobial activity in mixed extracts

For the purpose In the present study, the mixed extracts of Rumicis herba, Verbena officinalis, Sambucus nigra, Primula veris and preferred in combination with Gentiana lutea for the preparation of the agent according to the invention according to the declaration of Sinupret drops as well in a variant with a change in the ethanol concentration solvent produced.

Under the collective term "Rumicis herba "becomes one Understood mixture of the following species:

• Rumex acetosa L.
• Synonym: Lapathum acetosa SCOP.
• Synonym: Lapathum pratense LAM.
• Synonym: Acetosa pratensis MILLER
• Rumex acetosella L.
• Synonym: Rumex infestus SALISB.
• Rumex obtusifolius L.
• Synonym Lapathum obtusifolium MOENCH
• Synonym Lapathum obtusantum MONTAD.
• Synonym Rumex actus WALLR.
• Synonym Rumex silvestris WALLR.
• Rumex patientia L.
• Synonym Rumex olympicus BOISS.
• Synonym Lapathum hortense MOENCH
• Rumex crispus L.
• Rumex thyrsiflorus FINGERH.
• Synonym Acetosa thyrsiflora FINGERH.
• Synonym Rumex acetosa subsp. auriculatus WALLR.

The above species are medically allowed.

The term "Sinupret ^® mixture" means the extraction of Gentiana lutea, Rumicis herba, Verbena officinalis, Sambucus nigra and Primula Veris Rohdrogenmischung than 50 vol .-% ethanol.

The term "Sinupret ^® -Tropfen" means as drops completely formulated ethanol solution of extracts of Gentiana lutea, Rumicis herba, Verbena officinalis, Sambucus nigra, and Primula veris in 19 vol .-% ethanol.

In the 1 to 5 the results of the examination of the pharmaceutical preparation "Sinupret ^® corresponding extract (drug / extract ratio 1:11) as it is present in" Sinupret ^® drops ", and to an analog extract with a modified ethanol content in the extract, shown.

To simplify the presentation, the group Sinupret ^® -Tropfen and the other is called Sinupret ^® mixture.

Under Sinupret ^® mixture, a composition is hereinafter also understood that an ethanolic / aqueous extract of Gentiana lutea, Rumicis herba, Verbena officinalis, Sambucus nigra and Primula Veris ratio of 1: 3: 3: 3: contains. 3

The antimicrobial effect of the antimicrobial agent present was preferably using Sinupret ^® -Tropfen and Sinupret performed ^® mixture to a bacterial strain Panel reference for relevant Errege the upper respiratory tract. The same investigations were carried out on the mixture according to the invention, ie with extracts of Rumicis herba, Verbena officinalis, Sambucus nigra and Primula veris.

Furthermore were single extracts the individual plant drugs on their antimicrobial effect tested. This turned out to be surprising found out that each of the claimed individual drugs is an outstanding one antimicrobial activity in the test panel. These results are following the investigations in tabular form and with diagrams shown.

The while pathogens are Gram-positive cocci such as Staphylococcus aureus, Staphylococcus aureus MRSA, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus pneumoniae, Streptococcus mutans and Gramnegative bacilli such as Haemophilus influenzae and Enterobacteriaceae faecalis.

The used strains are at the American Type Culture Collection (Rockville, Maryland) commercially available with the following numbers: Staphylococcus aureus (ATCC 12600), Staphylococcus aureus MRSA (ATCC 33593), Staphylococcus epidermidis (ATCC 14990), Streptococcus pyogenes (ATCC 12344), Streptococcus pneumoniae (ATCC 33400), Streptococcus mutans (ATCC 35668), Haemophilus influenzae (ATCC 49247 and ATCC 33391) and Enterobacteriaceae faecalis (AER) (ATCC 51299).

The Target of the performed Investigation was the quantification of certain antimicrobial properties herbal extracts across from a reference strain panel of potential pathogens of infections of the upper respiratory tract, as well as multi-resistant pathogens.

The In vitro studies were performed in double-blind studies.

The test microorganisms were compared to the investigational medicinal product in concentrations of 10 ⁴ - 10 ⁵ / mL for 2 hours exposed. Of the test microbes subcultured on hard soils, the minimum bactericidal concentration, as well as the LD90 and LD50, both in% vol of the test volume, were determined.

Carrying out the investigations

1. Preparation of the investigational medicinal products

Various herbal extracts, PM 03-009 / 10 and PM 04-013 / 14, have been used as lyophilisates to at least substantially free them from ethanol (see 1 to 5 ).

The Lyophilisate was under the responsibility of Prof. Dr. med. Maune and dr. shepherd at the University Otolaryngology Clinic Kiel produced on a laboratory scale by means of a cryo-lyophilizate plant of Christ. there for cell culture Experiments an alcohol-free solution was mandatory (vitality of the examined cells) ; thus was a quicker Continuation of the experimental procedure ensured.

Explanation of the% volume "Information:
A defined volume of the solution provided by Bionorica AG was lyophilized. The lyophilisate was then taken up with the same volume, with only saline or cell culture solution.

The Quantities are to be understood as follows: The reconstituted lyophilisate was in a concentration of x% of the reconstituted lyophilisate (100%) used to achieve the described effect; Consequently x% of the solution provided by Bionorica AG described effect.

The Lyophilisate was first with sterile Aqua Best. with a quantity of 1/10 of the respective Initial volume solved and subsequently diluted 1:10 in the assay. The highest Concentration therefore corresponds to 100% vol based on the initial volume. The dilution took place in two-fold dilution steps of 100% Vol, 50% Vol, ..., 0.0125% Vol. A total of 14 Concentrations examined.

2. Preparation of the solid breeding grounds

Solid media and shake cultures were prepared from the following ingredients in a known manner. Sterile distilled water, 0.85% NaCl, sterile sodium phosphate buffer 10 mM, pH 7.0-7.4 (prepared from 1.78 g / L Na ₂ HPO ₄ .2H ₂ O and 1.38 g / L NaH ₂ PO ₄ * H ₂ O), Brain Heart Glucose Agar and Brain Heart Broth (BHI) (Difco), Columbia Altar + 5% Sheep Blood (Oxoid Company), Koch's Blood Altar, and Fildes Broth (Difco) used for the production of appropriate solid culture media for the cultivation of plate cultures and appropriate media for the cultivation of liquid cultures.

3. Production of precultures

In 10 mL brain-heart-glucose broth, overnight cultures of the test strains were cultured. Subsequently, subcultures of 50 μL or 100 μL of the bacterial suspensions were incubated in 10 mL brain-heart-glucose broth for 2.5 hours at 37 ° C in shake or stand cultures (strain-dependent). An absorbance reading was made against BHI broth as blank in the photometer at 578 nm. Subsequently, the cultures were centrifuged at 2800 rpm for 15 minutes and the pellets resuspended in 10 mL sodium phosphate buffer. An absorbance measurement was carried out against sodium phosphate buffer as a blank in the photometer at 578 nm. After preparation of appropriate calibration curves, the bacterial concentrations were each adjusted to 10 ⁴ - 10 ⁵ / ml in sodium phosphate buffer. Germ count was performed on BHI plates in serial dilutions of 10 ^-1 - 10 ^-3 in NaCl, the plated volume being 100 μL. The BHI plates were incubated for 21-22 hours at 37 ° C in the incubator.

The Incubation with extracts was carried out by charging a microtiter plate with 10 μL samples per Concentration in concentration steps of 100-0.0125% Vol. The concentration steps were carried out analogously to the concentration steps of the investigational medicinal products. The Microtiter plate was used for 2 hours at 37 ° C in Shaking Incubator cultured. The control was a bacterial suspension of 100 .mu.L + 10 .mu.L Aqua dest.

The germ count was determined according to DIN 58958-1 on BHI plates with NaCI dilution series of 10 ^-1 - 10 ^-3 , with a plated volume of 100 .mu.l. The BHI plates were incubated for 21-22 hours at 37 ° C in the incubator.

The evaluation of the antimicrobial effectiveness of the compositions used was carried out according to DIN 58940-1 by determining the MBK, LD90 and LD50. Their results are shown in Tables 1 to 5 and 1 to 5 specified.

Table 1: PM 03-009 Sinupret ^® mixture (Fig. 1)

Table 2: PM 03-009 Sinupret ^® mixture (Fig. 2)

Table 3: PM 04-013 Sinupret ^® mixture (Fig. 3)

Table 4: PM 03-010 Sinupret ^® -Tropfen (Fig. 4)

Table 5: PM 04-014 Sinupret ^® -Tropfen (Fig. 5)

When determining the above concentrations for MBK, LD90 and LD50, only the values were used, which were below 100, since only these values for a gentle and medically expedient application can be considered.

at determining the concentration ranges of MBK, LD90 and LD50 The smallest and largest became medically appropriate concentrations specified; the interval nesting of the concentration ranges results from the preferred concentration ranges, within der an application of the antimicrobial mixture of medical Point of view makes sense. The effect of the antimicrobial agent is natural also dependent on the concentration of bacteria.

There Escherichia coli (ATCC 11775) and Pseudomonas aeruginosa (ATCC 10145) as negative control were not affected by any of the extracts, The antimicrobial effect of the agents seems generic or species specific to be.

II. Detection of antimicrobial Effect on the individual drugs

The following tinctures were used in an analogous manner as the investigated mixed preparations under Chapter I. for bioassay with the test strains (also as lyophilisate, as described under I.):
Product name: PM03-004
Tinct. Verbenae herba, about 44 vol .-% ethanol.
Product name: PM03-005
Tinct. Rumicis herba, about 47 vol .-% ethanol
Product name: PM03-006
Tinct. Sambuci flos, about 44% ethanol by volume
Product name: PM03-007
Tinct. Primulae flos, about 46 vol .-% ethanol.

The results of the antimicrobial tests are shown in Tables 6 to 9 below and in the accompanying Tables 6 to 9 shown.

Table 6: Tinct. Primulae flos (Fig. 6)

Table 7: Tinct. Sambuci flos (Fig. 7)

Table 8: Tinct. Rumicis herba (Fig. 8)

Table 9: Tinct. Verbena herba (Fig. 9)

It thus showed a broad, pronounced antimicrobial effect the agent according to the invention both as a mixture as well as the individual drug extracts. The effect was evident especially opposite ENT-relevant pathogens, especially opposite Streptococcus pneumoniae and Streptococcus pyogenes and Staphylococcus aureus. The antimicrobial agent according to the present invention showed a pronounced Effectiveness against the Staphylococcus aureus MRSA strain, which is difficult to control. Its infectious Spread - especially in hospitals - could so far only by strict compliance with hospital hygiene Activities, such as the isolation of infected patients or antimicrobial Therapies of those affected, be prevented. These measures however, mean an extra Burden for the patients in both medical and psychological Respect.

With the agent of the invention Is it possible, especially in particularly affected places such as hospitals, one Prevent the spread of this multidrug-resistant pathogen and thus to protect the patient from further painful infections Way, i. use without synthetic chemical components to have to, to protect.

by virtue of the ENT relevance of the tested pathogens is the agent according to the invention also great everywhere where bacteria are directly and immediately locally or combat topically can.

The inventive agent can thus be preferred - in addition systemic application - immediate at the contaminated site, e.g. in the form of a biologically 100% degradable Disinfecting sprays or solution or of course also for direct topical application to skin and mucous membranes both be used on humans as well as on animals. There are different ones Forms of application. Particularly suitable are the formulations as a solution, Spray, creams, ointments and emulsions in the dermatological field human as well as veterinary medicine. Here the agent according to the invention can be used directly be applied to the diseased part of the skin and / or in shape of soaked Compresses, insoles or tamponades are used.

Of particular interest is the use of the agent according to the invention, of course, in the entire area of diseases of the entire respiratory tract, in particular the upper respiratory tract, here preferably in the area of the pharyngeal, nasal and paranasal sinus mucous membranes. Particular importance is attached to nasal rinsing, in particular in conjunction with salts, for example in combination with a physiological or hyperosmolar Emser ^salt® solution.

From Tonsillenpinsellösungen, gargles in pharyngeal infections to powder content preparations or nebuliser inhalation preparations extends the wide range of new applications.

Further Application and indication areas include wound and gum deposits, e.g. in the form of cotton liners or cotton thread liners which with the agent according to the invention soaked are.

As well conceivable are ear irrigation with solutions, the agent of the invention included, in ear canal infections.

Claims (15)

An antimicrobial agent, characterized in that it contains at least one plant drug or at least one ethanolic / aqueous extract thereof, the plants being selected from the group consisting of: Rumex acetosa L., Rumex obtusifolius L., Rumex patientia L. , and Rumex crispus L., (Rumicis herba); Verbena officinalis; Sambucus nigra; and primula veris; as well as their mixtures. Antimicrobial agent according to claim 1, characterized marked that in addition Gentiana lutea or an ethanolic / aqueous extract thereof. Antimicrobial agent according to claim 2, characterized characterized in that Ingredients of Gentiana lutea, Rumicis herba, Verbena officinalis, Sambucus nigra and Primula veris are present in a ratio of 1: 3: 3: 3: 3. Antimicrobial agent according to one of claims 1 to 3, characterized in that it effective against pathogen-relevant pathogens. Antimicrobial agent according to one of claims 1 to 4, characterized in that it against such respiratory - relevant Pathogen is effective, which are selected from the group consisting from: Gram-positive cocci, in particular Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus pneumoniae, Streptococcus mutans; Gram-negative rod bacteria, in particular Haemophilus influenzae; as well as their mixtures. Antimicrobial agent according to one of claims 1 to 5, characterized in that it against an oxacillin / methicillin resistant Staphylococcus aureus strain is effective. Antimicrobial agent according to one of claims 1 to 6, characterized in that it against such respiratory - relevant Pathogen is effective, the selected are from the group consisting of Staphylococcus aureus (ATCC 12600), Staphylococcus aureus (MRSA) (ATCC 33593) Staphylococcus epidermidis (ATCC 14990), Streptococcus pneumoniae (ATCC 33400), Streptococcus pyogenes (ATCC 12344), Streptococcus mutans (ATCC 35668), Haemophilus influenzae (ATCC 49247 and ATCC 33391); as well as their mixtures. Antimicrobial agent according to one of claims 1 to 3, characterized in that it against Enterobacteriaceae faecalis (VRE), in particular against Enterobacteriaceae faecalis (AER) (ATCC 51299). Antimicrobial agent according to one of claims 1 to 8, characterized in that it with a MBK of about 0.2 - 50 % Vol, especially about 0.2 - 30 % Vol, preferably about 0.2-12 % Vol and preferably about 0.2 - 3 % Vol, is effective. Antimicrobial agent according to one of claims 1 to 9, characterized in that it is an LD90 of about 0.1-50% Vol, in particular about 0.1-20% Vol, preferably about 0.1-10% Vol and preferably about 0.1-3% Vol. Antimicrobial agent according to one of claims 1 to 9, characterized in that it an LD50 of about 0.1 - 50 % Vol, especially about 0.1 - 20 % Vol, preferably about 0.1-10 % Vol and preferably about 0.1 - 3 % Vol. Antimicrobial agent according to one of claims 1 to 11 characterized in that it is present as a lyophilisate. An antimicrobial agent according to any one of claims 1 to 12, characterized in that the galenic formulation of antimicrobial agent is selected from the group consisting of: drops, juice, syrup, tablets, dragees, capsules, sustained-release formulations, rectal or vaginal suppositories, infusion , Spray, in particular nose and throat spray and disinfectant spray; Ointments, emulsions, powders, powders, liquid or solid preparations for inhalation, compresses, deposits, in particular wound and gum deposits, tamponades, including for teeth, rinsing solutions for nose and ear, in particular in combination with physiological and hyperosmolar concentrations of salts or salt mixtures , preferably saline, in particular sea salt or ^Emser® salt; and / or the formulation contains pharmaceutically customary auxiliaries. Kit with an antimicrobial agent according to at least one of the claims 1 to 13 in liquid or lyophilized form and at least one salt, for the preparation a nasal rinse solution. Kit according to claim 14, characterized in that the nasal rinse solution one physiological pH and a physiological salt concentration contains.